INDIANAPOLIS / Nov 04, 2024 / Business Wire / Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company’s growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company’s executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health’s Government Health Benefits business.
“Nate brings nearly two decades of experience spanning multiple sectors, including managed care, healthcare services, and consumer industries,” said Mark Kaye. “His diverse expertise, coupled with his analytical acumen will be instrumental in driving our strategy forward as we continue to evolve as a lifetime trusted health partner.”
Prior to joining Elevance Health, Mr. Rich served as Vice President in Global Investment Research at Goldman Sachs. He also held roles of increasing responsibility at Citi as a sell-side research analyst.
Mr. Rich holds a Bachelor of Science degree, magna cum laude, from New York University’s Leonard N. Stern School of Business.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Last Trade: | US$378.42 |
Daily Change: | -2.11 -0.55 |
Daily Volume: | 299,125 |
Market Cap: | US$87.760B |
April 22, 2025 January 23, 2025 October 17, 2024 July 17, 2024 April 18, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load